CN107412196B - 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 - Google Patents
奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN107412196B CN107412196B CN201710316871.8A CN201710316871A CN107412196B CN 107412196 B CN107412196 B CN 107412196B CN 201710316871 A CN201710316871 A CN 201710316871A CN 107412196 B CN107412196 B CN 107412196B
- Authority
- CN
- China
- Prior art keywords
- orlistat
- mpeg
- pcl
- nanoparticle
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001243 orlistat Drugs 0.000 title claims abstract description 115
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims abstract description 113
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 75
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 12
- 229920001427 mPEG Polymers 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 32
- 239000011780 sodium chloride Substances 0.000 claims description 26
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 23
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 18
- 150000002191 fatty alcohols Chemical class 0.000 claims description 16
- 206010001497 Agitation Diseases 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000012736 aqueous medium Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000012752 auxiliary agent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 abstract description 12
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- 229920000642 polymer Polymers 0.000 abstract description 5
- 239000004005 microsphere Substances 0.000 abstract description 4
- 239000002086 nanomaterial Substances 0.000 abstract description 4
- 239000004632 polycaprolactone Substances 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229960002668 sodium chloride Drugs 0.000 description 23
- 235000002639 sodium chloride Nutrition 0.000 description 23
- 239000007864 aqueous solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 235000013339 cereals Nutrition 0.000 description 10
- -1 concentration Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012046 mixed solvent Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 238000009777 vacuum freeze-drying Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000011805 ball Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 101000748159 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 35 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102100040048 Ubiquitin carboxyl-terminal hydrolase 35 Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical class CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
Abstract
Description
平均粒径(nm) | 载药率 | 包封率 | |
实施例2 | 92 | 15.6% | 86.2% |
实施例3 | 103 | 16.2% | 88.4% |
实施例4 | 126 | 17.3% | 87.8% |
实施例5 | 124 | 16.8% | 90.6% |
样品 | A549 | MCF7 | SH-SY5Y |
DOX | 0.66 | 0.51 | 0.88 |
奥利司他药物组 | 14.69 | 8.622 | 7.692 |
奥利司他纳米微球药物组 | 5.996 | 3.904 | 3.503 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710316871.8A CN107412196B (zh) | 2017-05-08 | 2017-05-08 | 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710316871.8A CN107412196B (zh) | 2017-05-08 | 2017-05-08 | 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107412196A CN107412196A (zh) | 2017-12-01 |
CN107412196B true CN107412196B (zh) | 2018-08-07 |
Family
ID=60425411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710316871.8A Active CN107412196B (zh) | 2017-05-08 | 2017-05-08 | 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107412196B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108524471B (zh) * | 2018-04-18 | 2019-03-01 | 中山万汉制药有限公司 | 奥利司他纳米微球及其在制备治疗肥胖症药物中的用途 |
CN108524472B (zh) * | 2018-04-18 | 2019-01-15 | 中山万汉制药有限公司 | 含有奥利司他的纳米微球在制备抗乙肝病毒药物中的用途 |
CN108578390B (zh) * | 2018-04-18 | 2019-02-26 | 中山万汉制药有限公司 | 含有奥利司他的纳米微球在制备抗肿瘤药物中的用途 |
CN108853060B (zh) * | 2018-09-06 | 2020-09-18 | 中山万汉制药有限公司 | 一种包含奥利司他的纳米微球及其制备方法和用途 |
CN111317717B (zh) * | 2020-04-20 | 2021-07-02 | 鲁南制药集团股份有限公司 | 奥利司他聚合胶束及其制备方法和在抗肿瘤药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011011978A1 (zh) * | 2009-07-31 | 2011-02-03 | 西安力邦医药科技有限责任公司 | 微球药物载体、其制备方法、组合物及应用 |
CN102670525A (zh) * | 2012-05-07 | 2012-09-19 | 李晓林 | 熊果酸纳米载药微球用于治疗肿瘤的用途及制备 |
-
2017
- 2017-05-08 CN CN201710316871.8A patent/CN107412196B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011011978A1 (zh) * | 2009-07-31 | 2011-02-03 | 西安力邦医药科技有限责任公司 | 微球药物载体、其制备方法、组合物及应用 |
CN102670525A (zh) * | 2012-05-07 | 2012-09-19 | 李晓林 | 熊果酸纳米载药微球用于治疗肿瘤的用途及制备 |
Non-Patent Citations (1)
Title |
---|
奥利司他抗肿瘤的研究进展;陈少波,等;《医学综述》;20150831;第21卷(第15期);摘要和第2735页最后一段 * |
Also Published As
Publication number | Publication date |
---|---|
CN107412196A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107412196B (zh) | 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 | |
Zhou et al. | Calcium phosphate-phosphorylated adenosine hybrid microspheres for anti-osteosarcoma drug delivery and osteogenic differentiation | |
Mohammadian et al. | Effects of chrysin-PLGA-PEG nanoparticles on proliferation and gene expression of miRNAs in gastric cancer cell line | |
CN108420793A (zh) | 一种空白混合胶束及其制备方法和应用 | |
CN110051845A (zh) | 一种mTOR抑制剂、药物组合物及其应用 | |
Zhu et al. | Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles | |
CN115252560B (zh) | 一种基于天然产物的自组装纳米粒及其制备方法和应用 | |
CN106344924B (zh) | 一种联合代谢阻断的纳米剂型及其耐药逆转应用 | |
Liu et al. | Paclitaxel/chitosan nanosupensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel | |
CN104163915A (zh) | 胆固醇-泊洛沙姆-胆固醇三嵌段共聚物及其制备方法和应用 | |
CN110840837B (zh) | 一种汉防己甲素纳米混悬液及其制备方法和应用 | |
CN106420664A (zh) | 一种具有抗癌活性的阿司匹林偶联物作为药物载体或者分子探针载体的应用 | |
CN107049944B (zh) | 一种可实现索拉非尼和姜黄素同时给药的聚合物胶束及其制备方法 | |
CN104306333A (zh) | 一种卡巴他赛脂质微球注射液及其制备方法 | |
Wu et al. | Amorphous silibinin nanoparticles loaded into porous starch to enhance remarkably its solubility and bioavailability in vivo | |
CN106361724B (zh) | 一种20(R)-人参皂苷Rg3缓释纳米微球组合及其制备方法 | |
CN103933016B (zh) | 一种辣椒碱三元纳米胶束及其制法和用途 | |
CN105012234B (zh) | 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途 | |
CN103768022B (zh) | 一种用作靶向性输送紫杉醇的自组装纳米粒、其制备方法和用途 | |
Eroglu | A resveratrol-loaded poly (2-hydroxyethyl methacrylate)-chitosan based nanotherapeutic: characterization and in vitro cytotoxicity against prostate cancer | |
Wang et al. | Inhibitory role of cucurbitacin B with polylactic acid nanoparticles carrying long non-coding RNA (LncRNA) cancer susceptibility candidate 2c (CASC2c) in oral cancer cell migration and invasion through targeting of signal transcription and activator of transcription (STAT) signaling pathway | |
CN115708829A (zh) | 一种抗骨质疏松药物组合物及其应用 | |
JP5774013B2 (ja) | シクロデキストリンのデオキシポドフィロトキシン包接錯体、その調製法、および癌治療への使用 | |
Kavousi et al. | Effect of coated carbon nanotubes with chitosan and cover of flaxseed in the induction of MDA-MB-231 apoptosis by analyzing the expression of Bax and Bcl-2 | |
CN113999279A (zh) | 哑铃型两亲性肽类树形分子、合成及其作为药物递送系统的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Orlistat nano-microsphere as well as preparation method and application thereof in anti-tumor drugs Effective date of registration: 20200221 Granted publication date: 20180807 Pledgee: Liangjiang branch of Chongqing Rural Commercial Bank Co.,Ltd. Pledgor: Chongqing Zen Pharmaceutical Co.,Ltd. Registration number: Y2020980000293 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 1-6, Jinfeng biomedical industrial park, No. 28, Gaoxin Avenue, Jiulongpo District, Chongqing Patentee after: Zhien Biotechnology Co.,Ltd. Address before: 400039 Jiulongpo District of Chongqing Science Park Road No. 73 of 25 layers Patentee before: Chongqing Zen Pharmaceutical Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220913 Granted publication date: 20180807 Pledgee: Liangjiang branch of Chongqing Rural Commercial Bank Co.,Ltd. Pledgor: Chongqing Zen Pharmaceutical Co.,Ltd. Registration number: Y2020980000293 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Orlistat nano-microspheres and preparation method thereof and application in antitumor drugs Effective date of registration: 20220919 Granted publication date: 20180807 Pledgee: Bank of Hankou Limited by Share Ltd. Chongqing branch Pledgor: Zhien Biotechnology Co.,Ltd. Registration number: Y2022500000071 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230911 Granted publication date: 20180807 Pledgee: Bank of Hankou Limited by Share Ltd. Chongqing branch Pledgor: Zhien Biotechnology Co.,Ltd. Registration number: Y2022500000071 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |